Shelter Pharma Ltd. (SHELTER) — Tipsheet

Shelter Pharma's Q1 exports hit ₹5 cr, nearly matching FY26 full year

Tipsheet Editorial — Fri, 19 Jun 2026 17:25:39 GMT

Q1 FY27 exports have already surpassed ₹5 crores, close to the ₹6 crores earned in all of FY26. The nano-cap also targets ₹200 crore revenue by FY30 with aggressive expansion.

What’s new

Exports in Q1 FY27 surpassed ₹5 crores, nearly equalling FY26's full-year export revenue of ₹6 crores.
FY26 revenue surged 44% to ₹73.13 crores; net profit stood at ₹9.03 crores.
Management targets ₹200 crore revenue by FY30, with pan-India expansion and a new Ahmedabad facility.

Why it matters

For a nano-cap with a market cap of ₹47 crores, quarter-one exports alone matching nearly the entire previous year's export revenue is a step-change. The trade-off is near-term margin pain – EBITDA dipped to 17% from 20-21% as the company invests in sales and distribution. If the ₹200 crore FY30 target is met, revenue would nearly triple, but the road involves capex of ₹12-15 crores and working capital improvement from 234 days to 60-30 days.

What we’re watching

Whether export momentum can sustain as new orders from Sudan and elsewhere flow in.
EBITDA margin recovery trajectory from 17% back to 22-25% over the next 2-3 years.
Progress on state expansion from 15 to 30 states and utilisation of the new Ahmedabad plant.

The full read

Shelter Pharma's post-results concall on June 19 delivered one standout number: ₹5 crores in Q1 FY27 exports, almost matching the ₹6 crores earned in all of FY26. For a ₹47 crore market-cap company, that is a dramatic acceleration. FY26 revenue of ₹73.13 crores grew 44% YoY, with net profit at ₹9.03 crores. The catch is EBITDA margin pressure – 17% versus the historical 20-21% – as management spends on sales team expansion and distribution. The longer-term target: ₹200 crores by FY30, driven by a move from 15 states to all 30, a ₹12-15 crore Ahmedabad plant, and higher-margin exports. Working capital at 234 days needs to come down to 60-30 days. For a nano-cap, the visibility is above average, but execution on state expansion and margin recovery will determine whether the ₹200 crore target is a stretch or a milestone.

Primary source: BSE · NSE

Shelter Pharma starts shipping ₹1.18 cr Sudan order

Tipsheet Editorial — Mon, 08 Jun 2026 19:08:00 GMT

The nano-cap Ayurvedic maker has already dispatched USD 118,634 of the USD 141,600 order for Joemega Capsules, with the rest in transit.

What’s new

Shelter Pharma is dispatching a USD 141,600 export order of Joemega Capsules to Taha Drugs & Chemicals in Sudan.
USD 118,634 of the order has already been shipped; the remaining USD 22,966 is next in the shipment plan.
The order is new business, not a previously announced shipment.

Why it matters

The order is small in absolute terms, but Shelter is a ₹51 crore market-cap company. This shipment represents about 2.3% of its current market capitalisation and 1.6% of its annual revenue of ₹73 crore. For a firm this size, a confirmed, partially shipped export order de-risks a portion of the topline and signals continued product demand in a new geography.

What we’re watching

Whether the final USD 22,966 ships on schedule and Taha Drugs takes full delivery.
If this Sudan connection leads to repeat or larger orders.
Shelter's revenue recognition timing for the dispatched goods.

The full read

Shelter Pharma, a nano-cap Ayurvedic manufacturer, has begun shipping a USD 141,600 order of Joemega Capsules to Sudan. The buyer is Taha Drugs & Chemicals. More than 83% of the order, valued at USD 118,634, is already in transit. The remainder ships next. For a company with a ₹51 crore market cap and ₹73 crore in annual revenue, the order is not trivial. It clocks in at 2.3% of market cap and 1.6% of revenue. The shipment is genuine new business and execution risk is dropping as the goods leave the factory. What matters next is whether this Sudan connection yields a repeat pipeline.

Primary source: BSE · NSE

Shelter Pharma locks in Gujarat manufacturing licence through 2030

Tipsheet Editorial — Tue, 02 Jun 2026 14:42:09 GMT

The Ayurvedic producer has renewed its key manufacturing authorisation, ensuring uninterrupted operations at its Himatnagar facility for the next five years.

What’s new

Shelter Pharma's Gujarat manufacturing licence has been renewed by the state's Food & Drugs Control Administration.
The approval covers production of Ayurvedic, Siddha and Unani drugs at its Himatnagar facility.
The new licence is valid until September 2030, providing long-term operational clarity.

Why it matters

For a nano-cap like Shelter Pharma, with a market cap of ₹54 crore, the loss of a key manufacturing licence would be existential. Renewal removes that risk for five years and validates the facility's compliance record. It is a routine but necessary event for continued business.

What we’re watching

Whether the company uses this stability to pursue new product lines or expansion.
The financial performance from the Himatnagar facility, which is central to revenue.
Any further regulatory actions or inspections at the plant.

The full read

Shelter Pharma has secured a five-year renewal of its manufacturing licence from Gujarat's Food & Drugs Control Administration. The approval covers the company's core production of Ayurvedic, Siddha and Unani drugs at its Himatnagar facility. For a nano-cap with a market cap of just ₹54 crore, this is not a growth catalyst but a necessity—the facility is central to its revenue, and a lapse would have been catastrophic. The renewal, valid until September 2030, confirms ongoing compliance and removes a key operational risk. It is a routine, positive regulatory step that provides long-term visibility.

Primary source: BSE · NSE